8-K: Tevogen Bio Secures $36 Million Credit Facility and Potential $14 Million Equity Investment

Tevogen Bio Holdings Inc. has entered into a loan agreement for a $36 million credit facility and a contingent option for a $14 million private equity placement.

Summary

• Tevogen Bio has secured a loan agreement with The Patel Family, LLP for a credit facility of up to $36 million.
• The agreement also includes a contingent option for the lender to purchase at least $14 million of Tevogen's common stock in a future private placement.
• The company can borrow up to $1 million per month under the facility, with the first draw eligible in June 2024.
• The monthly borrowing requests are available until May 2027 or until the proceeds from the private placement are received and no funds remain available under the facility.
• Interest on the loans will accrue quarterly at a rate equal to the lower of the secured overnight financing rate plus 2.00% or 7.00%, payable in shares of common stock at $1.50 per share.
• Each draw will mature 48 months after the disbursement date.
• Prepayment of the loan is permitted without penalty, and the company can repay in cash or shares of common stock at a price of at least $1.50 per share or the 10-day trailing volume weighted average price.
• The private placement option is priced at a 30% discount to the trailing volume weighted average price when it reaches at least $10.00 per share.
• Tevogen issued 1,000,000 shares of common stock to the lender as a commitment fee.
• The maximum number of shares issuable under the agreement is estimated to be 33.72 million, assuming maximum borrowing, no prepayments, maximum interest rate, payment of principal in shares, and the private placement is completed at $10.00 per share.
• The lender's ownership is capped at 9.99% of the outstanding common stock, with pre-funded warrants issued in lieu of common stock if this limit is exceeded.
• The cumulative number of shares issued to the lender without stockholder consent cannot exceed 19.99% of the outstanding shares on the agreement date.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company by securing a significant credit facility and potential equity investment. However, the potential for dilution and the contingent nature of the private placement temper the overall sentiment.

Positives

• The $36 million credit facility provides Tevogen Bio with significant financial flexibility.
• The option for a $14 million private placement could provide additional capital if the stock price reaches the threshold.
• Prepayment of the loan is permitted without penalty, offering flexibility in managing debt.
• The interest rate is capped at 7.00%, which could be beneficial if market rates increase.
• The ability to repay the loan in shares of common stock provides flexibility in managing cash flow.

Negatives

• The potential dilution of existing shareholders due to the issuance of shares for interest payments, loan repayment, and the private placement.
• The private placement is contingent on the stock price reaching $10.00 per share, which may not occur.
• The lender has the option to purchase additional shares beyond the $14 million, potentially increasing dilution.
• The company is obligated to issue 1,000,000 shares as a commitment fee, regardless of whether the loan is fully utilized.
• The interest rate, while capped, is still variable and tied to the secured overnight financing rate.

Risks

• The company may not be able to draw the full $36 million if the private placement is completed early.
• The stock price may not reach the $10.00 threshold required for the private placement, potentially limiting the company's access to additional capital.
• The issuance of a large number of shares could significantly dilute existing shareholders.
• The variable interest rate could increase the cost of borrowing if market rates rise.
• The lender's ownership cap of 9.99% could limit the amount of capital the company can raise from this source.

Future Outlook

The company has the option to draw on the credit facility until May 2027 or until the private placement is completed. The private placement is contingent on the stock price reaching $10.00 per share. The company may need to seek stockholder approval for additional share issuance if the lender's ownership exceeds certain thresholds.

Management Comments

• The document does not contain any direct quotes from management, but the agreement was signed by Ryan Saadi, Chief Executive Officer.

Industry Context

This type of financing agreement is common for biotechnology companies seeking to fund research and development and operations. The use of a credit facility with a contingent equity component allows the company to access capital while minimizing immediate dilution. The terms of the agreement, including the interest rate and private placement discount, are typical for companies of this size and stage.

Comparison to Industry Standards

• The interest rate of SOFR plus 2.00% or 7.00% is within the typical range for venture debt or similar financing for biotech companies.
• The private placement discount of 30% is a common incentive for investors in private placements, especially for companies with volatile stock prices.
• The use of pre-funded warrants to avoid exceeding ownership limits is a standard practice in these types of agreements.
• The 19.99% cap on share issuance without stockholder approval is a common provision to protect existing shareholders from excessive dilution.
• Comparable companies in the biotech sector often use similar financing structures, including venture debt with equity components, to fund their operations and development programs. For example, companies like Xencor and Arcus Biosciences have used similar financing methods.

Related Party Transactions

• The lender, The Patel Family, LLP, is an existing stockholder and an affiliate of Manmohan Patel, a beneficial owner of at least 5% of the common stock.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may benefit from the increased financial stability of the company.
• Customers and suppliers may see no immediate impact, but the financing could support future growth and development.
• Creditors may view the company as a more stable borrower due to the new financing.

Next Steps

• Tevogen Bio will begin drawing on the credit facility as needed.
• The company will monitor its stock price to determine if the private placement option becomes exercisable.
• The company will need to file a registration statement for the resale of the commitment shares and any shares issued under the agreement.
• The company may need to seek stockholder approval for additional share issuance if the lender's ownership exceeds certain thresholds.

Key Dates

Keywords

credit facility, loan agreement, private placement, common stock, warrants, financing, equity, dilution, interest rate, Tevogen Bio